beclometasone hydrofluoroalkane inhaler / Generic mfg. - LARVOL DELTA

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Chiesi Farmaceutici S.p.A.

New P1 trial • Asthma • Biosimilar • Chronic Obstructive Pulmonary Disease • Gene Therapies • Immunology

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P3; N=3686; Active, not recruiting; Sponsor: Chiesi Farmaceutici S.p.A.; Recruiting -> Active, not recruiting

Enrollment closed • Biosimilar • Chronic Obstructive Pulmonary Disease

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. (PubMed) - Lancet - P3; "We provide evidence for the clinical benefits of stepping up patients with COPD from an inhaled corticosteroid/long-acting β2-agonist combination treatment to triple therapy using a single inhaler."

Journal • Biosimilar • Chronic Obstructive Pulmonary Disease

Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis (clinicaltrials.gov) - P4; N=68; Recruiting; Sponsor: Stefania La Grutta, MD; Not yet recruiting ➔ Recruiting

Enrollment open • Biosimilar • Immunology

Analysis of cytogenetic alterations in asthmatic patients treated with beclometasone dipropionate (ERS 2018) - "The increased MN levels in buccal epithelial cells in patients treated with ICSs may be attributed to local irritate effect of ICS. This finding confirms the necessity of the practice of oral cavity hygiene after ICS use. "

Clinical • Asthma • Biosimilar • Immunology • Respiratory Diseases

PrIGMa: Preschool Wheeze: Inflammation/Infection Guided Management (clinicaltrials.gov) - P2; N=60; Completed; Sponsor: Imperial College London; Recruiting ➔ Completed; Trial completion date: Dec 2018 ➔ Aug 2018; Trial primary completion date: Dec 2018 ➔ Aug 2018

Trial completion • Trial completion date • Trial primary completion date

Functional Respiratory Imaging Study (FRI) (clinicaltrials.gov) - P3; N=20; Completed; Sponsor: Chiesi Farmaceutici S.p.A.; Recruiting ➔ Completed; N=30 ➔ 20; Trial completion date: Jun 2019 ➔ Jan 2019

Clinical • Enrollment change • Trial completion • Trial completion date

STORM: Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Chiesi Farmaceutici S.p.A.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

STORM: Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Chiesi Farmaceutici S.p.A.

Clinical • New P1 trial